ATE292976T1 - Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung - Google Patents

Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung

Info

Publication number
ATE292976T1
ATE292976T1 AT99922905T AT99922905T ATE292976T1 AT E292976 T1 ATE292976 T1 AT E292976T1 AT 99922905 T AT99922905 T AT 99922905T AT 99922905 T AT99922905 T AT 99922905T AT E292976 T1 ATE292976 T1 AT E292976T1
Authority
AT
Austria
Prior art keywords
cell survival
blood cell
white blood
mobilization
producing
Prior art date
Application number
AT99922905T
Other languages
English (en)
Inventor
Kathleen Rodgers
Gere Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE292976T1 publication Critical patent/ATE292976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99922905T 1998-05-11 1999-05-10 Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung ATE292976T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8490898P 1998-05-11 1998-05-11
US9263398P 1998-07-13 1998-07-13
PCT/US1999/010205 WO1999058140A1 (en) 1998-05-11 1999-05-10 Methods to increase white blood cell survival after chemotherapy

Publications (1)

Publication Number Publication Date
ATE292976T1 true ATE292976T1 (de) 2005-04-15

Family

ID=26771571

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922905T ATE292976T1 (de) 1998-05-11 1999-05-10 Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung

Country Status (8)

Country Link
US (2) US6475988B1 (de)
EP (1) EP1073453B1 (de)
JP (1) JP2003521441A (de)
AT (1) ATE292976T1 (de)
AU (1) AU759285B2 (de)
CA (1) CA2322963C (de)
DE (1) DE69924715T2 (de)
WO (1) WO1999058140A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU2591699A (en) * 1998-02-09 1999-08-23 University Of Southern California Method of promoting erythropoiesis
US7173011B2 (en) * 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6762167B1 (en) * 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) * 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
EP3517134B1 (de) * 2001-12-17 2024-01-17 The Trustees of the University of Pennsylvania Sequenzen von adeno-assoziierte viren (aav) vom serotyp 8, vektoren enthaltend solche sequenzen und verwendungen dafür
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
WO2009114461A2 (en) * 2008-03-10 2009-09-17 University Of Southern California Angiotensin (1-7) dosage forms and uses thereof
EP2455388A1 (de) 2010-11-23 2012-05-23 LanthioPep B.V. Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür
MX2012010783A (es) 2011-02-02 2012-11-23 Univ Southern California Metodos para tratar ulceras del pie diabetico.
WO2013172956A1 (en) 2012-05-14 2013-11-21 University Of Southern California Methods for limiting development of a skin wound
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CA2902619A1 (en) 2013-03-15 2014-09-25 University Of Southern California Methods for treating multiple sclerosis
AU2014233185B2 (en) 2013-03-15 2018-03-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
JP6254692B2 (ja) 2013-07-03 2017-12-27 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ 認知機能不全を治療するための方法
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
US5527882A (en) * 1989-07-07 1996-06-18 The Regents Of The University Of California Polypeptide having an amino acid replaced with N-benzylglycine
CA2044468C (en) * 1990-11-21 2006-08-22 Richard A. Nash Canine granulocyte macrophage colony stimulating factor
US5578643A (en) 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
ATE210677T1 (de) 1993-09-24 2001-12-15 Univ Southern California Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
EP1333034B1 (de) 1993-09-24 2010-07-14 University Of Southern California Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
JP3403794B2 (ja) * 1994-01-27 2003-05-06 仙味エキス株式会社 血圧降下剤及び血圧降下性機能食品
US5595973A (en) 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
US5739110A (en) * 1994-09-12 1998-04-14 Biomeasure Inc. Protection of hemopoietic cells
US5614515A (en) 1994-11-17 1997-03-25 University Of Southern California Lazaroid-based compositions and method for preventing adhesion formation using the same
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
WO1996040090A1 (en) 1995-06-07 1996-12-19 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
WO1997034627A2 (en) 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection of hemopoietic cells during chemotherapy or radiotherapy
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU6650098A (en) 1997-02-04 1998-08-25 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999026644A1 (en) * 1997-11-26 1999-06-03 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6165978A (en) * 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
AU2591699A (en) * 1998-02-09 1999-08-23 University Of Southern California Method of promoting erythropoiesis

Also Published As

Publication number Publication date
DE69924715T2 (de) 2006-01-26
EP1073453A1 (de) 2001-02-07
DE69924715D1 (de) 2005-05-19
WO1999058140A1 (en) 1999-11-18
AU3979899A (en) 1999-11-29
CA2322963C (en) 2004-04-13
JP2003521441A (ja) 2003-07-15
US6475988B1 (en) 2002-11-05
EP1073453B1 (de) 2005-04-13
US6566335B1 (en) 2003-05-20
AU759285B2 (en) 2003-04-10
CA2322963A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
ATE292976T1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
MA23744A1 (fr) Procede pour la preparation de sulfonamides, compositions pharmaceutiques les contenant et leur utilisation
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
AU6331898A (en) Forskohlin for promoting lean body mass
EP0863755A4 (de) Antithrombotische diamine
ATE210677T1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
AP9801269A0 (en) Prostaglandin agonists.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
DE59308848D1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
ATE250422T1 (de) Komponenten mit niedrigem molekulargewicht aus knorpelgewebe von haien, verfahren zur herstellung und therapeutische verwendungen
PH30665A (en) Aminosulfonyl urea acat inhibitors
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE69722202D1 (de) Dihydrobenzopyran und ähnliche verbindungen verwendbar als antientzündungsmittel
WO2005017160A3 (en) Mobilization of hematopoietic cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties